Cargando…
Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
Imiquimod is a topical toll-like-receptor-7 agonist currently used for treating basal cell carcinoma. Recently, imiquimod has demonstrated tumor regression in melanoma and breast cancer skin metastases. However, the molecular perturbations induced by imiquimod in breast cancer metastases have not be...
Autores principales: | Rozenblit, Mariya, Hendrickx, Wouter, Heguy, Adriana, Chiriboga, Luis, Loomis, Cynthia, Ray, Karina, Darvishian, Farbod, Egeblad, Mikala, Demaria, Sandra, Marincola, Francesco M., Bedognetti, Davide, Adams, Sylvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561945/ https://www.ncbi.nlm.nih.gov/pubmed/31189943 http://dx.doi.org/10.1038/s41598-019-42784-9 |
Ejemplares similares
-
Values and conduc
por: Margolis, Joseph
Publicado: (1971) -
Characterization of soils conducive and non-conducive to Prunus replant disease
por: Khan, Abdur R., et al.
Publicado: (2021) -
The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
por: Bertucci, François, et al.
Publicado: (2018) -
Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection
por: Hartmann, Ann-Kathrin, et al.
Publicado: (2023) -
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
por: Panelli, Monica C, et al.
Publicado: (2007)